Dr. Lizza Hendriks

🎤 Presentation: Neoadjuvant chemoimmunotherapy in NSCL
In this presentation the evidence for neoadjuvant and perioperative chemo-immunotherapy for resectable NSCLC will be discussed, and whether we can make borderline resectable NSCLC, resectable

💬 Biography
Dr Hendriks is a pulmonologist specialising in thoracic oncology at the Maastricht University Medical Center, the Netherlands, where she leads the clinical lung cancer research department. Her research line is focussing on brain metastases in patients with lung cancer (obtaining a PhD on this topic in 2016), neurocognition, oligometastases and locally advanced disease. In 2017-2018, she carried out postdoctoral research on brain metastases and immunotherapy in Gustave Roussy, France.
Dr Hendriks is the representative for thoracic oncology in the Maastricht UMC Comprehensive Cancer Cancer, and chairs the Innovative Cancer Diagnostics Therapy group at the Research Institute for Oncology and Developmental Biology (GROW) at Maastricht University, where she is also appointed as full professor. She is heavily involved in clinical and translational research, and is (local) principal investigator in several phase II and III clinical trials, focusing on (locally) advanced NSCLC and SCLC, targeted treatments and immunotherapies.
She is an active member of Dutch (NVALT, NRS), European (ESMO, EORTC, ETOP, ERS) and global societies (IASLC, ASCO), is chair of the NVALT studies foundation, vice-chair of the scientific committee of the Dutch Thoracic Group and secretary of the EORTC Lung Cancer Group.
Dr Hendriks was the lead author of the revised ESMO Clinical Practice Guidelines on metastatic NSCLC and author of several other ESMO Clinical Practice Guidelines as well as several Dutch guidelines. Dr Hendriks is an active program committee member or chair of multiple national and international conferences and masterclasses. In 2021, she was elected as member of the Young Academy of the Royal Netherlands Academy of Arts and Sciences.